|Articles|February 10, 2014
Certara Offers TQT Assessment Tool
Product helps to determine whether a drug candidate prolongs cardiac repolarization, a surrogate for potentially-fatal arrhythmias
Advertisement
Certara, which offers software and scientific consulting services for drug development, announced the launch of itsPhoenix QT+ cardiac safety assessment tool. This product provides data processing, statistical, and modeling capabilities in regard to Thorough QT (TQT) study requirements under the ICH E14 Guidelines (ICH, 2005). The product provides a comprehensive analysis of electrocardiogram (ECG) interval data collected in TQT studies and sub-studies in other clinical trials to determine whether a drug is at risk for cardiac depolarization prolongation.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
2
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
5